Antenatal magnesium sulfate: Neuro-protection for preterm infants

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 100, Issue 6, 2015, Pages F553-F557

  Oddie, S ^a,b   Tuffnell, D J ^a,b   McGuire, W ^b,c  

^a BRADFORD ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c York Teaching Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; NEUROPROTECTIVE AGENT;

APNEA; ARTICLE; CEREBRAL PALSY; COST EFFECTIVENESS ANALYSIS; ECLAMPSIA; HEALTH CARE POLICY; HUMAN; MUSCLE HYPOTONIA; MUSCLE WEAKNESS; NEONATOLOGIST; NEUROPROTECTION; PRACTICE GUIDELINE; PREECLAMPSIA; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; TOCOLYSIS; UNITED KINGDOM; FEMALE; NEWBORN; PREGNANCY;

CEREBRAL PALSY; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENTS; PREGNANCY;

EID: 84955586298     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/archdischild-2014-307655     Document Type: Article

References (46)

1. de Kleine MJ, den Ouden AL, Kollée LA, et al. Lower mortality but higher neonatal morbidity over a decade in very preterm infants. Paediatr Perinat Ep 2007;21:15-25.
2. Spittle AJ, Orton J. Cerebral palsy and developmental coordination disorder in children born preterm. Semin Fetal Neonatal Med 2014;19:84-9.
3. Bax M, Goldstein M, Rosenbaum P, et al. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 2005;7:571-6.
4. McIntyre S, Novak I, Cusick A. Consensus research priorities for cerebral palsy: a Delphi survey of consumers, researchers, and clinicians. Dev Med Child Neurol 2010;52:270-5.
5. Oskoui M, Coutinho F, Dykeman J, et al. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. Dev Med Child Neurol 2013;55:509-19.
6. Platt MJ, Cans C, Johnson A, et al. Trends in cerebral palsy among infants of very low birthweight (<1500 g) or born prematurely (>32 weeks) in 16 European centres: a database study. Lancet 2007;369:43-50.
7. Novak I, Hines M, Goldsmith S, et al. Clinical prognostic messages from a systematic review of cerebral palsy. Paediatrics 2012;130:e1285-312.
8. Himpens E, Van den Broeck C, Oostra A, et al. Prevalence, type, distribution, and severity of cerebral palsy in relation to gestational age: a meta-analytic review. Dev Med Child Neurol 2008;50:334-40.
9. Moore T, Hennessy EM, Myles J, et al. Neurological and developmental outcome in extremely preterm children born in England in 1995 and 2006: the EPICure studies. BMJ 2012;345:e7961.
10. Marret S, Doyle LW, Crowther CA, et al. Antenatal magnesium sulphate neuroprotection in the preterm infant. Semin Fetal Neonatal Med 2007;12:311-17.
11. Macdonald RL, Curry DJ, Aihara Y, et al. Magnesium and experimental vasospasm. J Neurosurg 2004;100:106-10.
12. Mami AG, Ballesteros J, Mishra OP, et al. Effects of magnesium sulfate administration during hypoxia on Ca (2+) influx and IP (3) receptor modification in cerebral cortical neuronal nuclei of newborn piglets. Neurochem Res 2006;31:63-70.
13. Fritz KI, Mishra OP, Delivoria-Papadopoulos M. Mg2+-dependent modification of the N-methyl-D-aspartate receptor following graded hypoxia in the cerebral cortex of newborn piglets. Neuroscience 1999;92:685-92.
14. Laires MJ, Monteiro CP, Bicho M. Role of cellular magnesium in health and human disease. Front Biosci 2004;9:262-76.
15. Rantonen TH, Gronlund JU, Jalonen JO, et al. Comparison of the effects of antenatal magnesium sulphate and ritodrine exposure on circulatory adaptation in preterm infants. Clin Physiol Funct Imaging 2002;22:13-17.
16. Macones GA, Sehdev HM, Berlin M, et al. Evidence for magnesium sulfate as a tocolytic agent. Obstet Gynecol Surv 1997;52:652-8.
17. Crowther CA, Brown J, McKinlay CJ, et al. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2014;8:CD001060.
18. Duley L, Gülmezoglu AM, Henderson-Smart DJ, et al. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010;11:CD000025.
19. Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the collaborative eclampsia trial. Lancet 1995;345:1455-63.
20. Neilson JP. Magnesium sulphate: the drug of choice in eclampsia. BMJ 1995;311:702.
21. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995;95:263-9.
22. Schendel DE, Berg CJ, Yeargin-Allsopp M, et al. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996;276:1805-10.
23. Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009;1:CD004661.
24. Mittendorf R, Dambrosia J, Pryde PG, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002;186:1111-18.
25. Crowther CA, Hiller JE, Doyle LW, et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. JAMA 2003;290:2669-76.
26. Magpie Trial Follow Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG 2007;114:289-99.
27. Marret S, Marpeau L, Zupan-Simunek V, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. PREMAG trial group. BJOG 2007;114:310-18.
28. Rouse DJ, Hirtz DG, Thom E, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008;359:895-905.
29. Doyle LW, Anderson PJ, Haslam R, et al. Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Study Group. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA 2014;312:1105-13.
30. Chollat C, Enser M, Houivet E, et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. J Pediatr 2014;165:398-400.
31. Smith JM, Lowe RF, Fullerton J, et al. An integrative review of the side effects related to the use of magnesium sulphate for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth 2013;13:34.
32. De Jesus LC, Sood BG, Shankaran S, et al, Eunice Kennedy Shriver National Institute of Health and Human Development Neonatal Research Network. Antenatal magnesium sulfate exposure and acute cardiorespiratory events in preterm infants. Am J Obstet Gynecol 2015;212:94. e1-7.
33. Weisz DE, Shivananda S, Asztalos E, et al. Intrapartum magnesium sulfate and need for intensive delivery room resuscitation. Arch Dis Child Fetal Neonatal Ed 2015;100:F59-65.
34. Bickford CD, Magee LA, Mitton C, et al. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res 2013;13:527.
35. AMICABLE Group. Antenatal magnesium individual participant data international collaboration: assessing the benefits for babies using the best level of evidence (AMICABLE). Syst Rev 2012;1:21.
36. Cahill AG, Caughey AB. Magnesium for neuroprophylaxis: fact or fiction? Am J Obstet Gynecol 2009;200:590-4.
37. Brok J, Huusom LD, Thorlund K. Conclusive meta-analyses on antenatal magnesium may be inconclusive! Are we underestimating the risk of random error? Acta Obstet Gynecol Scand 2012;91:1247-51.
38. Huusom LD, Brok J, Hegaard HK, et al. Does antenatal magnesium sulfate prevent cerebral palsy in preterm infants? The final trial? Acta Obstet Gynecol Scand 2012;91:1346-7.
39. American College of Obstetricians and Gynecologists. Committee Opinion No. 455. Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol 2010;115:669-71.
40. The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: National clinical practice guidelines. Adelaide: The University of Adelaide, 2010.
41. Crowther CA, Middleton PF, Bain E, et al. WISH Project Team. Working to improve survival and health for babies born very preterm: the WISH project protocol. BMC Pregnancy Childbirth 2013;13:239.
42. Crowther CA, Middleton PF, Wilkinson D, et al. MAGENTA Study Group. Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)-study protocol. BMC Pregnancy Childbirth 2013;13:91.
43. Royal College of Obstetricians and Gynaecologists. Magnesium sulphate to prevent cerebral palsy following preterm birth: Scientific impact paper no. 29. 2011. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/sip29/ (accessed Dec. 2014).
44. Sinclair JC. Meta-analysis of randomized controlled trials of antenatal corticosteroid for the prevention of respiratory distress syndrome: discussion. Am J Obstet Gynecol 1995;173:335-44.
45. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006;3:CD004454.
46. Ow LL, Kennedy A, McCarthy EA, et al. Feasibility of implementing magnesium sulphate for neuroprotection in a tertiary obstetric unit. Aust N Z J Obstet Gynaecol 2012;52:356-60.